Clinical Trial Update: Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial is evaluating dissolved phase Xenon-129 MRI as a biomarker to quantify pulmonary pathology in electronic cigarette–related lung injur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• E-cigarette or Vaping Product Use-associated Lung Injury

Snippet

Sponsor: Y. Michael Shim, MD | Conditions: Electronic Cigarette Related Lung Damage | Phase 2, Phase 3 | Status: RECRUITING